Search results for "LIVER TRANSPLANTATION"

showing 10 items of 359 documents

Performance of Gd-BOPTA Magnetic Resonance in the diagnosis of Hepatocellular Carcinoma, compared to histology after orthotopic liver transplantation.

liver transplantation.Magnetic ResonanceHepatocellular CarcinomaGd-BOPTA; Magnetic Resonance; Hepatocellular Carcinoma; liver transplantation.Gd-BOPTA
researchProduct

Ischemic type biliary lesions in histidine-tryptophan-ketoglutarate (HTK) preserved liver grafts.

2006

Ischemic type biliary lesions lead to considerable morbidity following orthotopic liver transplantation. The exact pathogenesis is unknown. One major hypothesis is that insufficient perfusion of the arterial vessels of the biliary tree, especially under perfusion with the high viscous University of Wisconsin solution, might be responsible for ischemic type biliary lesions. Due to low viscosity, HTK solution is reported to have a lower incidence of biliary complications. However, there is no data concerning ischemic type biliary lesions in HTK preserved livers. In this paper we report our results after orthotopic liver transplantation with special regard to ischemic type biliary lesions in …

medicine.medical_specialtyAdenosinemedicine.medical_treatmentAllopurinolOrgan Preservation Solutions030232 urology & nephrologyBiomedical EngineeringMedicine (miscellaneous)Bioengineering030204 cardiovascular system & hematologyLiver transplantationHTK solutionGastroenterologyPotassium ChlorideBiomaterialsPathogenesisHistidine-tryptophan-ketoglutarate03 medical and health sciences0302 clinical medicineRaffinoseIschemiaInternal medicinemedicineHumansInsulinViaspanMannitolProspective Studiesbusiness.industryImmunosuppressionGeneral MedicineOrgan PreservationMiddle AgedGlutathioneLiver TransplantationTransplantationGlucoseBile DuctsbusinessPerfusionProcaineThe International journal of artificial organs
researchProduct

Control Of Organ Transplant-Associated Graft-versus-Host Disease By Activated Host Lymphocyte Infusions

2004

Background Prolonged persistence of donor-derived T cells after organ transplantation has been proposed to improve long-term allograft survival. However, surviving transplant-derived T cells are also able to mediate devastating graft-versus-host disease (GvHD). Currently, GvHD after organ transplantation is usually refractory to conventional therapy and the disease outcome fatal. Methods Graft-reactive host T cells were generated ex vivo from a patient suffering from a severe and refractory liver-transplant-associated GvHD. To control GvHD, activated alloreactive host T cells were repetitively retransferred into the patient (activated host lymphocyte infusion [aHLI]). Results Adoptive trans…

medicine.medical_specialtyAdoptive cell transferLymphocytemedicine.medical_treatmentGraft vs Host Diseasechemical and pharmacologic phenomenaLymphocyte ActivationImmunotherapy AdoptiveSeverity of Illness IndexOrgan transplantationBlood Transfusion AutologousmedicineHumansAgedTransplantationbusiness.industryImmunotherapymedicine.diseaseAdoptive TransferLiver TransplantationTransplantationsurgical procedures operativeGraft-versus-host diseasemedicine.anatomical_structureLymphocyte TransfusionImmunologyFemaleStem cellEpidermolysis BullosabusinessEx vivoTransplantation
researchProduct

Stretching the boundaries for liver transplant in the 21st century.

2018

Given the high waiting list mortality, there is a clear need to identify strategies to increase the number of livers for transplantation. Some strategies require policy changes, whereas others depend on a better understanding of available opportunities. We divided the strategies to increase the number of livers for transplantation into two categories-those aiming to increase the use of organs considered to be of suboptimal quality, and those aiming to increase the use of organs considered to be of suboptimal size. Enough evidence suggests that, if considered in the context of other donor and recipient variables, grafts from elderly donors are a safe option. The severity of steatosis, and no…

medicine.medical_specialtyBrain DeathWaiting ListsContext (language use)030230 surgery03 medical and health sciencesLiver disease0302 clinical medicinemedicineLiving DonorsHumansIntensive care medicineCause of deathMachine perfusionHepatologybusiness.industryFatty liverGastroenterologyAge FactorsHepatitis Cmedicine.diseaseHepatitis CTissue DonorsLiver TransplantationTransplantationFatty LiverDonationKidney Failure Chronic030211 gastroenterology & hepatologybusinessThe lancet. Gastroenterologyhepatology
researchProduct

Italian association for the study of the liver position statement on SARS-CoV2 vaccination.

2021

The vaccination campaign against Sars-CoV-2 commenced in Italy at the end of December 2020. The first ones to receive the immunization against the virus were the health workers and the residents of nursing homes, following which the vaccine would be available for the entire population, beginning with the most vulnerable individuals. SARS-CoV2 vaccines have been demonstrated to be safe for the general population, although no data for patients with liver diseases or those having undergone liver transplantation are available so far. The present position statement AISF is an attempt to suggest, based on the published data on the impact of Sars-Cov-2 infection in patients with chronic liver dise…

medicine.medical_specialtyCOVID-19 VaccinesSars-CoV-2medicine.medical_treatmentPopulationLiver transplantationChronic liver diseaseRisk AssessmentPatient safetyEpidemiologyMedicineChronic liver disease Sars-CoV-2 Vaccination Humans Immunosuppressive Agents Italy Liver Transplantation Patient Safety Patient Selection Risk Adjustment Risk Assessment SARS-CoV-2 Transplant Recipients Treatment Outcome COVID-19 COVID-19 Vaccines Immunization Programs Liver DiseasesHumanseducationeducation.field_of_studyHepatologybusiness.industryImmunization ProgramsLiver DiseasesPatient SelectionChronic liver disease; Sars-CoV-2; VaccinationVaccinationChronic liver diseaseGastroenterologyCOVID-19medicine.diseaseTransplant RecipientsLiver TransplantationVaccinationTreatment OutcomeImmunizationItalyFamily medicineChronic liver disease; Sars-CoV-2; Vaccination; Humans; Immunosuppressive Agents; Italy; Liver Transplantation; Patient Safety; Patient Selection; Risk Adjustment; Risk Assessment; SARS-CoV-2; Transplant Recipients; Treatment Outcome; COVID-19; COVID-19 Vaccines; Immunization Programs; Liver DiseasesRisk AdjustmentPatient SafetyPosition PaperbusinessRisk assessmentImmunosuppressive AgentsDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Therapeutic Effectiveness of Nutrition Therapy in Pediatric Patients with Chronic Liver Diseases Awaiting Liver Transplantation

2013

It is important to prevent protein/calorie malnutrition in children with end stage liver diseases prior to transplantation. This study involved 34 patients between the ages of 10 and 156 months (mean value 25.69 months ± 32.2) (13 females and 21 males) on the liver transplant waiting list. Data collected as of three months before transplant and up to ten months after the procedure concerned gender, age, weight, height, Pediatric End Stage Liver Disease Score, baseline pathology, type of nutrition, type of transplant, immunosuppression, pulse steroid therapy, length of stay, and post transplant complications. Linear regression analysis showed that the length of hospital stay was 24.5 days mo…

medicine.medical_specialtyCaloriebusiness.industrymedicine.medical_treatmentImmunosuppressionTransplant Waiting ListLiver transplantationmedicine.diseaseSettore BIO/09 - Fisiologianutrition therapy pediatric patients liver transplantationSurgeryTransplantationMalnutritionInternal medicinemedicinePopulation studyMedical nutrition therapybusinessJournal of Food Research
researchProduct

Management of hepatitis C virus genotype 4: recommendations of an international expert panel.

2011

HCV has been classified into no fewer than six major genotypes and a series of subtypes. Each HCV genotype is unique with respect to its nucleotide sequence, geographic distribution, and response to therapy. Genotypes 1, 2, and 3 are common throughout North America and Europe. HCV genotype 4 (HCV-4) is common in the Middle East and in Africa, where it is responsible for more than 80% of HCV infections. It has recently spread to several European countries. HCV-4 is considered a major cause of chronic hepatitis, cirrhosis, hepatocellular carcinoma, and liver transplantation in these regions. Although HCV-4 is the cause of approximately 20% of the 170 million cases of chronic hepatitis C in th…

medicine.medical_specialtyCarcinoma HepatocellularGenotypeHepatitis C virusHepacivirusHepacivirusmedicine.disease_causeAntiviral AgentsPolymorphism Single NucleotideFlaviviridaeInternal medicineGenotypeEpidemiologyRibavirinmedicineHumansClinical Trials as TopicHepatologybiologybusiness.industryInterleukinsLiver Neoplasmsvirus diseasesHepatitis CHepatitis C Chronicbiology.organism_classificationmedicine.diseaseVirologydigestive system diseasesRecombinant ProteinsLiver TransplantationNatural historyHepatocellular carcinomaInterferon Type IPractice Guidelines as TopicHCVInterferonsbusiness
researchProduct

Impact of margin status on long-term results of liver resection for hepatocellular carcinoma: single-center time-to-recurrence analysis

2020

Occult metastasis from the initial tumor and a de novo second primary hepatocellular carcinoma (HCC) were recognized as the main causes for the onset of early and late HCC recurrence, after liver resection (LR). This study aims to compare the time to recurrence after LR for HCC in which a margin ≤ 1 mm or > 1 mm was achieved. A single-center retrospective study involving 256 patients was conducted from June 2005 to June 2019. HCC patients resected with a radical surgical approach were investigated and stratified into groups A (resection margins ≤ 1 mm) and B (> 1 mm), as measured on final pathologic assessment. Kaplan–Meier estimators were used to estimate the probability of recurrenc…

medicine.medical_specialtyCarcinoma HepatocellularTime FactorsHepatocellular carcinomaHepatocellular carcinoma; Liver resection; Liver transplantation; Margin status; Outcome030230 surgerySingle CenterGastroenterologyGroup BMetastasis03 medical and health sciences0302 clinical medicineInternal medicineHepatocellular carcinoma Liver resection Liver transplantation Margin status Outcome Carcinoma Hepatocellular Liver Neoplasms Neoplasm Recurrence Local Neoplasms Second Primary Time Factors Hepatectomy Margins of ExcisionEpidemiologyHepatectomyHumansMedicineMargin statusPathologicalOutcomeLiver transplantationLiver resectionbusiness.industryProportional hazards modelLiver NeoplasmsMargins of ExcisionNeoplasms Second PrimaryRetrospective cohort studymedicine.diseaseSurgery030220 oncology & carcinogenesisHepatocellular carcinomaSurgeryNeoplasm Recurrence Localbusiness
researchProduct

Transarterial Chemoembolization Before Liver Transplantation in 60 Patients With Hepatocellular Carcinoma

2007

Tumor recurrence is a major problem after orthotopic liver transplantation (OLT) in patients with hepatocellular carcinoma (HCC). In 60 patients OLT was performed for HCC after pretreatment by repeated transarterial chemoembolization (TACE). Forty-four recipients exceeded the Milan criteria. Recurrence-free 5-year survival was 65.2% and 5-year freedom from recurrence was 73.2%. During the waiting time, 14 patients experienced minimal change, which did not fulfill the definition of tumor progression according to official oncological criteria. Five-year freedom from recurrence among patients with stable compared with progressive disease was 93.3% versus 28.1%, respectively (P = .0001). A stri…

medicine.medical_specialtyCarcinoma HepatocellularTime Factorsmedicine.medical_treatmentLiver transplantationMilan criteriaGastroenterologyDisease-Free SurvivalRecurrenceInternal medicinePreoperative CaremedicineHumansEmbolizationChemoembolization TherapeuticTransplantationbusiness.industryPatient SelectionLiver Neoplasmsmedicine.diseaseSurvival AnalysisLiver TransplantationSurgeryTransplantationTumor progressionHepatocellular carcinomaSurgerybusinessLiver cancerProgressive diseaseTransplantation Proceedings
researchProduct

Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre

2019

BACKGROUND: The recurrence of hepatocellular carcinoma (HCC) is the strongest survival-limiting factor after liver transplantation (LT) in patients with HCC. In the face of donor organ shortage, it is necessary to identify factors associated with HCC recurrence in order to maximize the utility of the available grafts. OBJECTIVE: To study the phenomenon of HCC recurrence after LT at a European transplantation centre over the past 20 years. METHODS: Data from 304 HCC patients who underwent LT were prospectively recorded. Clinical and pathological factors were assessed for their association with recurrence. RESULTS: Fifty-one patients (16.8%) had HCC recurrence after LT. Patients exceeding the…

medicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentEconomic shortageLiver transplantationGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansIn patientneoplasmsProportional Hazards Modelsbusiness.industryLiver NeoplasmsGastroenterologyOriginal Articlesmedicine.diseasePrognosisdigestive system diseasesLiver TransplantationTransplantationEuropeTreatment OutcomeOncology030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyNeoplasm Recurrence LocalbusinessLiver cancer
researchProduct